MRNA Jun 2024 240.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 10:40AM EDT. Market open.
| Previous close | 0.0900 |
| Open | 0.0900 |
| Bid | 0.0000 |
| Ask | 0.0600 |
| Strike | 240.00 |
| Expiry date | 2024-06-21 |
| Day's range | 0.0900 - 0.0900 |
| Contract range | N/A |
| Volume | |
| Open interest | 333 |
Yahoo FinanceNovavax stock doubles after Sanofi deal marks 'new chapter' for company
Novavax stock popped Friday on news of a licensing deal and minority stake from Big Pharma player Sanofi.
- Yahoo Finance Video
Moderna: FDA postpones RSV vaccine approval
Moderna (MRNA) has announced a setback in the anticipated approval of its RSV vaccine. The biopharmaceutical company says that the US Food and Drug Administration (FDA) has postponed the decision to approve the vaccine until the end of May due to administrative constraints. Yahoo Finance's health reporter Anjalee Khemlani breaks down the details. For more expert insight and the latest market action, click here to watch this full episode of Catalysts. This post was written by Angel Smith
Investor's Business DailyModerna Seesaws After The FDA Throws A Curveball On Its Second Product
Moderna stock seesawed Friday after the Food and Drug Administration delayed an approval decision on its RSV vaccine until the end of the month.
© 2024 Yahoo. All rights reserved.